New research published in Molecular Biology Reports finds that CBD may help protect insulin-producing pancreatic cells in the ...

NSCLC remains the leading cause of cancer-related mortality worldwide, with EGFR mutations being a critical driver in approximately 10-15% of lung adenocarcinomas in Western populations, and up to 40% ...

The company said that the acquisition adds Faeth’s lead investigational therapy, PIKTOR, to its oncology portfolio.

Sensei Biotherapeutics, Inc. SNSE surged on Wednesday following the company’s announcement of its acquisition of Faeth Therapeutics Inc. and a concurrent $200 million private investment. The ...

Acquisition of Faeth and concurrent $200 million private investment positions the combined company to advance its pipeline across key clinical milestones in endometrial and breast cancerPIKTOR is an ...

Only a couple of months ago, Sensei Biotherapeutics was laying off staff and mulling winding down the company. | Only a couple of months ago, Sensei Biotherapeutics was laying off staff and mulling ...

Investing.com -- Sensei Biotherapeutics (NASDAQ:SNSE) stock soared 200% Wednesday after the company announced its acquisition ...

This narrative review examines how micro- and nanoplastics may contribute to oxidative stress, inflammation, and metabolic ...

Chip’s deep experience commercializing significant oncology drugs will provide valuable insight to Celcuity as we advance our programs and prepare for the potential approval and launch of gedatolisib ...

Oral presentation to highlight updated Phase 1 monotherapy safety and efficacy data for TOS-358, a covalent PI3Ka inhibitorData will include ...

MINNEAPOLIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its ...